Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, posted the following on X:
“Intratumoral pembrolizumab and mRNA-2752 for high-risk DCIS: Phase 1 nonrandomized trial
- 80% response rate
- No major systemic toxicities
- Complete tumor resolution in some cases, possibly reducing surgery
Ongoing studies are needed.”
